Anti-PLA2g10 antibodies and methods of use
WO2025049908A1PCT designated stage expired Publication Date: 2025-03-06NORMUNITY INC
3 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2024/044675
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-01
- Filing Date
- 2024-08-30
- Publication Date
- 2025-03-06
AI Technical Summary
Technical Problem
There is a need for therapies targeting PLA2G10, as it promotes cancer cell proliferation and survival, and is involved in cancer progression by releasing lipid mediators.
Method used
Development of antibodies and polypeptides that specifically bind to PLA2G10, which can attenuate the inhibition of immune cell migration caused by PLA2G10, thereby treating cancer.
Benefits of technology
The antibodies and polypeptides effectively inhibit the enzymatic activity of PLA2G10, enhancing T cell infiltration into tumors and providing a therapeutic approach for cancer treatment.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure IMGF000089_0001 
Figure IMGF000014_0001 
Figure IMGF000015_0001
Abstract
The present disclosure provides antibodies and polypeptides that specifically bind to phospholipase A2 group X (PLA2G10). Also provided are compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Antibodies Anti-spla2-x and uses thereof
US20140370030A1
Human monoclonal Anti-PD-l1 antibodies and methods of use
WO2014055897A2
Systems and methods for expressing biomolecules in a subject
WO2022067091A1